Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Hospital-acquired human bocavirus in infants

G.S. Durigona,*, D.B.L. Oliveira, S.B. Vollet, J.G. Stormi, M.C.C. Felício, C. Finelli, J. Piera, M. Magalhães, R.N. Caldeira, M.L. Barbosa, E.L. Durigon, E.N. Berezina

*Department of Paediatrics, Santa Casa de Misericórdia Hospital, São Paulo, Brazil
†Department of Microbiology, Institute of Biomedical Science, University of São Paulo, Brazil

SUMMARY

Human bocavirus (HBoV) is a respiratory pathogen that affects young children. We screened 511 nasopharyngeal aspirates for hospital-acquired HBoV from infants hospitalised with respiratory infection from January to December 2008. Among 55 children with HBoV infection, 10 cases were hospital-acquired. Compared with the community-acquired cases, coinfection with other respiratory viruses in these patients was uncommon. HBoV should be considered for inclusion in screening protocols for nosocomial childhood respiratory infections, especially in intensive care units.

© 2010 The Hospital Infection Society. Published by Elsevier Ltd. All rights reserved.

Introduction

Human bocavirus (HBoV) is a newly recognised respiratory pathogen that mainly affects children aged <2 years.1 It is a member of the Paroviridae family, subfamily Parvovirinae, genus bocavirus. Since its first description in 2005 by Allander et al., it has been found worldwide in respiratory specimens from children with lower respiratory tract (LRT) infection with a prevalence varying from 1.5% to 19%.2,3 HBoV has also been isolated from faeces of children with gastroenteritis, with or without respiratory symptoms.4 Recent studies have described two novel HBoV groups, named HBoV2 and HBoV3.5

Publications addressing the epidemiology of nosocomial respiratory virus infection are scarce. A few authors have reported cases of nosocomial HBoV infection, mostly acquired in intensive care units.6–8 As a potential new agent of nosocomial childhood infection, we screened for HBoV in young children with respiratory tract infection.

Methods

The data presented are part of a prospective study on the aetiology of childhood respiratory infections being carried out at Santa Casa de Misericórdia Hospital, São Paulo, Brazil. Santa Casa is a tertiary reference hospital located in the central region of São Paulo City.

From January 2008 to December 2008, nasopharyngeal aspirates (NPAs) were collected from children aged <2 years and screened for respiratory viruses including HBoV. Two groups of children were screened: (1) children on the paediatric ward or intensive care unit (ICU) with clinically suspected LRT infection and (2) infants who had been in the neonatal ICU (NICU) since birth. On the NICU, NPAs were collected from those with suspected LRT infection, and once a week from asymptomatic infants who were receiving mechanical ventilation.

NPAs were stored in liquid nitrogen and sent weekly to the virology laboratory of the University of São Paulo for detection of respiratory virus by polymerase chain reaction (PCR).9 All samples were tested for the following respiratory viruses: respiratory syncytial virus, human metapneumovirus, parainfluenza virus 1, 2 and 3, influenza virus A and B and adenovirus. PCR and reverse transcription (RT)–PCR assays were developed based on previous publications using GeneScan analysis with primers previously described.10–12 PCR for HBoV was performed using primers previously described targeting the NS1 gene.13 All HBoV-positive samples were amplified by a second PCR using primers based on a conserved region of the VP1/VP2 gene: HBoVP1 (5' ACCACCAAGTACTTAGAACTGG 3') and HBoVP2 (3' AATAGTCCCTGGAGATGATCC 5'). The expected product size was 657 bp. In most cases these products were sequenced for phylogenetic analysis. Sequences were edited with the sequence navigator program version 1.0 (Applied Biosystems, Inc., Foster City,
CA, USA) and the phylogenetic tree was created by the clustal method using Megalign (Lacergene, DNA STAR, Inc., Madison, WI, USA).

The study was approved by the Research Ethics Committee of Santa Casa de Misericórdia Hospital and by the University of São Paulo. Written informed consent was obtained from the parent or guardian of each child enrolled in the study.

Results

A total of 511 NPA were collected from 406 children: 381 samples were collected from 359 children in the paediatric ward and ICU, while 130 were collected from 47 infants in the NICU. Fifty-five samples (10.7%) were positive for HBoV, with a higher prevalence between May and August.

Ten of the HBoV infections were definitely or probably acquired in the hospital. Four infants had been in the NICU since birth (patients 1, 2, 3 and 10) while four infants admitted from the community had previously tested negative for HBoV (patients 4, 6, 7 and 9). One infant (patient 8) was in the paediatric ICU following liver transplantation and developed respiratory distress 28 days after admission. The final patient (patient 5) was in the paediatric ward being treated for visceral leishmaniasis and developed LRT infection 17 days after admission. The characteristics of the patients with hospital-acquired HBoV are described in Table 1.

Among the 45 presumed community-acquired HBoV infections, 23 (51.1%) were coinfected with at least one other respiratory virus, particularly adenovirus and respiratory syncytial virus (RSV) (in nine cases each). Of the 10 hospital-acquired infections, only one was coinfected (adenovirus).

Phylogenetic analysis of eight of the 10 HBoV amplicons revealed three different strains of HBoV group 1 with 99.6–99.8% similarity (Figure 1). Two amplicons (representing patients 8 and 10) were not sequenced.

Discussion

Nosocomial HBoV infection has been recently described. Kesebir et al. reported three children who were infected in the hospital, all of whom had a history of premature birth and chronic lung disease.6 Chow et al. reported three cases of nosocomial HBoV, two in the NICU.8 Calvo et al. described two newborns with HBoV in the NICU, both premature and receiving mechanical ventilation.7 In this paper we describe 10 further cases of nosocomial HBoV infection in children and infants. Sequence analysis of eight of the infecting viruses revealed three different strains of HBoV group 1, denominated A (six cases), B (one case) and C (one case).

Among these 10 children, only one was coinfected with another respiratory virus (adenovirus). Previous reports of HBoV infection suggest rates of coinfection with other respiratory viruses of up to 75%.14 The low rate of coinfection in hospital-acquired compared with community-acquired HBoV may reflect the diminished circulation of respiratory virus in the hospital setting. We did not screen our samples for rhinovirus or coronavirus.

One child had undergone liver transplantation 27 days before HBoV was detected and was under intense immunosuppression. The role of HBoV infection in immunocompromised children is not well-defined. Recent studies report persistence of HBoV DNA in NPA of healthy individuals up to four months after infection.15 In this case, since no previous sample was available, it is possible that the infection represented reactivation of previous community HBoV infection due to immunosuppression.

The finding of HBoV in four NICU infants hospitalised since birth raises the question of maternal–fetal transmission. However, three of these children (patients 2, 3 and 10) had been in the NICU for more than two weeks when the virus was detected, and the fourth (patient 1) was seven months old, so it is more likely to have been acquired postnatally.

Hospital-acquired respiratory virus infection can increase morbidity and mortality in hospitalised children, mainly the younger ones and those with underlying conditions. We have

Table 1

| Patient number | Month of HBoV detection | Hospital daysa | Age (months) | Sex | Hospital setting | Relevant clinical features | Relevant laboratory and radiographic featuresb | Mechanical ventilation/related to HBoVc | Underlying condition | Coinfectiond | HBoV strain |
|----------------|-------------------------|----------------|--------------|-----|-----------------|---------------------------|---------------------------------------------|-----------------------------------------|---------------------|----------------|--------------|
| 1              | Jan 238                 | 7 F NICU       | Fever, respiratory distress, wheezing | None | Yes/No          | CLD/Prem                  | No A                                        |                          |                    |               |              |
| 2              | Feb 19                  | 0 F NICU       | Fever, respiratory distress | None | Yes/Yes         | CLD/Prem/CHD              | No A                                        |                          |                    |               |              |
| 3              | Jul 29                  | 1 F NICU       | Respiratory distress | None | No/No           | CLD/CHD                   | No B                                        |                          |                    |               |              |
| 4              | Jul 138                 | 5 M PICU 2     | Respiratory distress | Leucocytosis, increased CRP | Yes/No | CLD/Prem/CHD/CHD | No A                                        |                          |                    |               |              |
| 5              | Jul 17                  | 10 M PWard     | Cough, fever, fast breathing | Pneumonia | No/No          | Visc Leish                | No A                                        |                          |                    |               |              |
| 6              | Jul 65                  | 8 M PICU 1     | Fever, respiratory distress, wheezing | Pneumonia | Yes/No          | CLD/Prem/CHD/CHD          | No A                                        |                          |                    |               |              |
| 7              | Aug 81                  | 3 M PICU 2     | Fever, respiratory distress, wheezing | Leucocytosis, increased CRP | Yes/No | CLD/Prem/CHD/CHD | No A                                        |                          |                    |               |              |
| 8              | Sep 29                  | 12 F PICU 1    | Fever, respiratory distress | Increased CRP | Yes/Yes | Liver TX                  | No ND                                       |                          |                    |               |              |
| 9              | Oct 526                 | 25 M PICU 2    | Fever, respiratory distress, wheezing | Leucocytosis, increased CRP, pneumonia | Yes/No |CLD/CHD                  | No ND                                       |                          |                    |               |              |
| 10             | Dec 20                  | 0 F NICU       | Respiratory distress | None | Yes/No           | Prem/CLD/CHD              | No C                                        |                          |                    |               |              |

NICU, neonatal intensive care unit; PICU, paediatric intensive care unit; PWard, paediatric ward; CLD, chronic lung disease; Prem, history of prematurity; CHD, congenital heart disease; Visc Leish, visceral leishmaniasis; Liver TX, post liver transplantation; Adeno, adenovirus; HBoV, human bocavirus; ND, not done; CRP, C-reactive protein.

a Number of days between hospital admission and HBoV detection.

b Leucocytosis ≥20 000 leucocytes; increased CRP ≥5 mg/dL (normal values <0.5); alveolar and/or non-alveolar pneumonia detected by chest radiography.

c Patients under mechanical ventilation regardless of HBoV infection/related to acute nosocomial HBoV infection.

d Detection of other respiratory virus (respiratory syncytial virus, human metapneumovirus, parainfluenza virus 1, 2 and 3, influenza virus A and B and adenovirus) by polymerase chain reaction assay in the samples analysed.
demonstrated that HBoV can be detected from infants with clinical evidence of nosocomial respiratory infection as well as those with community-acquired infection.

Conflict of interest statement
None declared.

Funding source
This study has been partially supported by grants from the CNPq — Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazil; project number 472537/2007-5.

References
1. Arnold J, Singh K, Spector S, Sawyer M. Human bocavirus: prevalence and clinical spectrum at a children’s hospital. Clin Infect Dis 2006;43:283–288.
2. Allander T, Tammi M, Ericsson A, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci USA 2005;102:12891–12896.
3. Allander T. Human bocavirus. J Clin Virol 2008;41:29–33.
4. Albuquerque M, Rocha L, Benati F, et al. Human bocavirus infection in children with gastroenteritis in Brazil. Emerg Infect Dis 2007;13:1756–1758.
5. Arthur JL, Higgins GD, Davidson GP, Givney RC, Ratcliff RM. A novel Bocavirus associated with acute gastroenteritis in Australian Children. PLoS Pathol 2009;5:e1000391.
6. Kesebir D, Vazquez M, Weibel C, et al. Human bocavirus infection in young children in the United States: molecular epidemiological profile and clinical characteristics of a newly emerging respiratory virus. J Infect Dis 2006;194:1276–1282.
7. Calvo C, García-García ML, Blanco C, et al. Human bocavirus infection in young children in the United States: molecular epidemiological profile and clinical characteristics of a newly emerging respiratory virus. J Infect Dis 2006;194:1276–1282.
8. Chow BDW, Huang YT, Esper FP. Evidence of human bocavirus circulating in children and adults, Cleveland, Ohio. J Clin Virol 2008;43:302–306.
9. Thomazelli LM, Vieira S, Leal AL, et al. Surveillance of eight respiratory viruses in clinical samples of pediatric patients in southeast Brazil. J Pediatr 2007;83:422–428.
10. Erdman DD, Weinberg GA, Edwards KM, et al. GeneScan reverse transcription–PCR assay for detection of six common respiratory viruses in young children hospitalized with acute respiratory illness. J Clin Microbiol 2003;41:4296–4303.
11. Falsey AR, Erdman DD, Anderson LJ, Walsh EE. Human metapneumovirus infection in young and elderly adults. J Infect Dis 2003;187:785–790.
12. Xu W, Erdman DD. Type-specific identification of human adeno virus 3, 7 and 21 by multiplex PCR assay. J Med Virol 2001;64:537–542.
13. Sloots TP, McErlean P, Speicher DJ, et al. Evidence of human coronavirus HKU1 and human bocavirus in Australian children. J Clin Virol 2006;35:99–102.
14. Bonzel L, Tenenbaum T, Schroten H, Schildgren O, Schweitzer-Krantz S, Adams O. Frequent detection of viral coinfection in children hospitalized with acute respiratory tract infection using a real-time polymerase chain reaction. Pediatr Infect Dis J 2008;27:589–594.
15. Blessing K, Nesse F, Herre U, Krieth HW, Weissbrich B. Prolonged detection of human bocavirus DNA in nasopharyngeal aspirates of children with respiratory tract disease. Pediatr Infect Dis J 2009;28:1018–1019.